Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

This study is testing a combination of two targeted drugs — axatilimab (which targets a protein called CSF1R) and ruxolitinib (a JAK inhibitor) — in people with myelofibrosis or chronic myelomonocytic leukemia (CMML), two types of blood cancers. **You may be eligible if...** - You are 18 or older - You have been diagnosed with myelofibrosis (MF) or CMML - For MF: you have had at least one prior MF therapy, or have had a suboptimal response to a JAK inhibitor for at least 3 months, or have newly diagnosed intermediate-risk MF - For CMML: your disease did not respond to hydroxyurea or you have tried at least 4 cycles of a hypomethylating agent **You may NOT be eligible if...** - Your disease has progressed to acute leukemia - You have active serious infections or uncontrolled other illnesses - You have significant heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.